Fennec Pharmaceuticals Inc's Customers Performance

Name: Fennec Pharmaceuticals Inc Customers by Division and Industry - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use

FENC

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.


FENC's Source of Revenues		During the corresponding time, Fennec Pharmaceuticals Inc recorded a revenue increase by 85.18 % year on year, sequentially revenue grew by 18.31 %. While revenue at the Fennec Pharmaceuticals Inc 's corporate clients • List of FENC Customers

for the same period Fennec Pharmaceuticals Inc recorded revenue increase by 85.18 % year on year, sequentially revenue grew by 18.31 %.

• List of FENC Customers

Fennec Pharmaceuticals Inc's Business Units


Manufactured Product Other	180.55 %	of total Revenue
Service Other	3.97 %	of total Revenue

Select the Relationship:

Customers ▼

Select the Category:

Comparison ▼

Customers ▼

Basic Report▼

Fennec Pharmaceuticals Inc's Comment on Sales, Marketing and Customers

News about Fennec Pharmaceuticals Inc Contracts

Evolving Pediatric Care Fennec Pharmaceuticals Pedmarqsi Gains NICE Green Light to Combat Cisplatin-Induced H...

In a significant advancement in pediatric healthcare, Fennec Pharmaceuticals has received a positive recommendation from the National Institute for Health and Care Excellence (NICE) for its groundbreaking treatment, Pedmarqsi (anhydrous sodium thiosulfate). This marks a pivotal moment for children and young adults, aged between one month and 17 years, who are subjected to the potentially debilitating side effects of cisplatin, a chemotherapy drug commonly used in the treatment of various cancers.Cisplatin is known for its efficacy in oncological treatments; however, one of its grave consequences is ototoxicity, which can lead to irreversible hearing loss in young patients. This perilous side effect not only ...

Fennec Pharmaceuticals' Strategic Licensing Deal with Norgine Marks a Milestone for Pediatric Cancer Treatment

Fennec Pharmaceuticals, a renowned pharmaceutical company specializing in the development of innovative therapies for cancer treatment, has recently entered into an exclusive licensing agreement with Norgine to commercialize PEDMARQSI in Europe, Australia, and New Zealand. This groundbreaking partnership combines Norgine s commercial expertise and extensive European footprint with PEDMARQSI, a revolutionary therapy that has gained approval as the first and only treatment in the European Union and U.K. for reducing the risk of cisplatin-induced hearing loss in pediatric patients with localized, non-metastatic solid tumors.PEDMARQSI has generated significant interest and excitement within the medical and pharm...

FENC's Stock Performance relative to it's Customers

FENC's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Fennec Pharmaceuticals Inc	424.41	51.00	-8.38	35
SUBTOTAL	0.00	0.00	0.00	-

Sources: Fennec Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Fennec Pharmaceuticals Inc’s corporate clients.
For your research, we’ve provided 9 tables on Fennec Pharmaceuticals Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.